Trial Profile
Use of Botulinum Toxin (BTX) for the Treatment of Peripheral Painful Traumatic Trigeminal Neuropathy (PPTTN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Trigeminal neuralgia
- Focus Therapeutic Use
- Acronyms TRIGTOX
- 07 Apr 2023 Status changed from active, no longer recruiting to completed.
- 27 Jun 2022 Planned End Date changed from 1 Apr 2023 to 1 Dec 2022.
- 27 Jun 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Jul 2022.